The Danish company Novo Nordisk launched a tablet form of Wegovy, a popular anti-obesity drug.[1][2][7] The US FDA has approved this oral version, which is the first GLP-1 tablet designed for weight loss.[1][2][4] The pill is taken once a day and helps to lose weight just like the original injectable form.[1][2] The company is offering a discount for cash payers - $149 a month for the lowest benefits until April 15.[7] The Phase III OASIS-4 study demonstrated significant reductions in body weight versus placebo and improvements in cardiovascular markers.[4] The tablet contains 25 mg of oral semaglutide and is intended for adults with obesity in combination with diet and exercise.[4][8] Novo Nordisk works with telehealth providers to recruit new patients.[7] The price of the pill has not yet been officially confirmed, but it is expected to be lower than the injection.[1][2]